These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 1355678)

  • 21. Expression of N-acetyltransferase (NAT) in cultured human uroepithelial cells.
    Kloth MT; Gee RL; Messing EM; Swaminathan S
    Carcinogenesis; 1994 Dec; 15(12):2781-7. PubMed ID: 8001235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Markers of genetic susceptibility in human environmental hygiene and toxicology: the role of selected CYP, NAT and GST genes.
    Thier R; Brüning T; Roos PH; Rihs HP; Golka K; Ko Y; Bolt HM
    Int J Hyg Environ Health; 2003 Jun; 206(3):149-71. PubMed ID: 12872524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status.
    Osawa Y; Osawa KK; Miyaishi A; Higuchi M; Tsutou A; Matsumura S; Tabuchi Y; Tsubota N; Takahashi J
    Asian Pac J Cancer Prev; 2007; 8(1):103-8. PubMed ID: 17477782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility.
    Zhong S; Howie AF; Ketterer B; Taylor J; Hayes JD; Beckett GJ; Wathen CG; Wolf CR; Spurr NK
    Carcinogenesis; 1991 Sep; 12(9):1533-7. PubMed ID: 1680031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Role of gene polymorphisms of phase II of xenobiotic biotransformation from glutathione-S-transferase and N-acetyltransferase families in susceptibility to lung cancer among Mayak workers].
    Rusinova GG; Azizova TV; Viazovskaia NS; Glazkova IV; Gur'ianov MIu; Osovets SV
    Radiats Biol Radioecol; 2014; 54(4):350-9. PubMed ID: 25775823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genotype and allele frequencies of N-acetyltransferase 2 and glutathione S-transferase in the Iranian population.
    Torkaman-Boutorabi A; Hoormand M; Naghdi N; Bakhshayesh M; Milanian I
    Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1207-11. PubMed ID: 17880378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls.
    Dolzan V; Rudolf Z; Breskvar K
    Carcinogenesis; 1995 Nov; 16(11):2675-8. PubMed ID: 7586185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype and phenotype of glutathione S-transferase class mu isoenzymes mu and psi in lung cancer patients and controls.
    Brockmöller J; Kerb R; Drakoulis N; Nitz M; Roots I
    Cancer Res; 1993 Mar; 53(5):1004-11. PubMed ID: 8439946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CYP2D6 genes and risk of liver cancer.
    Agúndez JA; Ledesma MC; Benítez J; Ladero JM; Rodríguez-Lescure A; Díaz-Rubio E; Díaz-Rubio M
    Lancet; 1995 Apr; 345(8953):830-1. PubMed ID: 7898230
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.
    Broly F; Marez D; Sabbagh N; Legrand M; Millecamps S; Lo Guidice JM; Boone P; Meyer UA
    Pharmacogenetics; 1995 Dec; 5(6):373-84. PubMed ID: 8747409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.
    Dahl ML; Johansson I; Palmertz MP; Ingelman-Sundberg M; Sjöqvist F
    Clin Pharmacol Ther; 1992 Jan; 51(1):12-7. PubMed ID: 1346258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology.
    Steen VM; Andreassen OA; Daly AK; Tefre T; Børresen AL; Idle JR; Gulbrandsen AK
    Pharmacogenetics; 1995 Aug; 5(4):215-23. PubMed ID: 8528268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of polymorphic expression of CYP2D6 mRNA in bladder mucosa and tumor tissue to in vivo debrisoquine hydroxylase activity.
    Romkes-Sparks M; Mnuskin A; Chern HD; Persad R; Fleming C; Sibley GN; Smith P; Wilkinson GR; Branch RA
    Carcinogenesis; 1994 Sep; 15(9):1955-61. PubMed ID: 7923590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer.
    Hirvonen A; Husgafvel-Pursiainen K; Anttila S; Karjalainen A; Vainio H
    Environ Health Perspect; 1993 Oct; 101 Suppl 3(Suppl 3):109-12. PubMed ID: 7908263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer.
    Cascorbi I; Brockmöller J; Mrozikiewicz PM; Bauer S; Loddenkemper R; Roots I
    Cancer Res; 1996 Sep; 56(17):3961-6. PubMed ID: 8752164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study.
    Evans WE; Relling MV
    Mol Pharmacol; 1990 May; 37(5):639-42. PubMed ID: 1971090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolutionary pharmacogenetics of CYP2D6 in Ngawbe Guaymi of Panama: allele-specific PCR detection of the CYP2D6B allele and RFLP analysis.
    Jorge LF; Arias TD; Griese U; Nebert DW; Eichelbaum M
    Pharmacogenetics; 1993 Oct; 3(5):231-8. PubMed ID: 7904509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. pNAT and CYP2D6 gene polymorphism in epileptic patients.
    Borlak JT; Harsany V; Schneble H; Haegele KD
    Biochem Pharmacol; 1994 Nov; 48(9):1717-20. PubMed ID: 7980640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias.
    Lemos MC; Cabrita FJ; Silva HA; Vivan M; Plácido F; Regateiro FJ
    Carcinogenesis; 1999 Jul; 20(7):1225-9. PubMed ID: 10383893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.